Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of GSK5764227 versus topotecan in relapsed small cell lung cancer
MOH_2025-11-19_015474Phase 3Recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of risvutatug rezetecan and topotecan in small cell lung cancer (SCLC) (2 arms), sponsored by GSK. Primary endpoints: Antitumor activity and Overall survival. Started Oct 2025; status: recruiting.
02
Drugs
risvutatug rezetecantopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2025-11-19_015474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-19_015474.